^
Association details:
| Biomarker: | MET positive |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | GST-HG16 (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Excerpt:
...Patients with solid tumors confirmed c-Met positive by testing....
Trial ID:
Source:
Title:
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple administration, dose escalation, and expanded phase I trial
Excerpt:
...Patients with solid tumors confirmed c-Met positive by testing. ...
Trial ID:
Less C2 evidence
Source:
Title:
First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor. Add to Collection
Published date:
05/28/2020
Excerpt:
...6 patients (CRC 2, Gastric 1, NSCLC 1, HCC 1, Cholangiocarcinoma 1) were enrolled to 3 dose levels (60, 150, and 300 mg). Of these 6 patients, 4 had discontinued GST-HG161 treatment at the data cut-off date of Feb 1, 2020, due to progressive disease (3) and adverse event (1). Two patients at the 300 mg cohort are still on treatment. Overall, 4/6 patients showed no drug related AEs > Grade 1....GST-HG161 has been well tolerated to date in study patients with a manageable safety profile.
DOI:
10.1200/JCO.2020.38.15_suppl.e16126
